Botulinum Neurotoxin Biohybrid

The present invention relates to a novel botulinum neurotoxin (BoNT) Heavy Chain Binding domain (HC/TAB) adapted to synergistically bind to a synaptotagmin (Syt) receptor, a synaptic associated vesicle 2 (SV2) receptor and a ganglioside (Gang) receptor, as well as polypeptides comprising said novel HC/TAB, vectors encoding said polypeptides, and uses thereof.